Metastatic melanoma: results of ‘classical' second-line treatment with cytotoxic chemotherapies
- 2 September 2012
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 25 (5) , 396-400
Abstract
Background: Metastatic melanoma is one of the most aggressive tumours, with a median survival that does not exceed 12 months. None of the cytotoxic first-line therapies have shown survival benefit in randomised clinical trials. Objective: To describe clinical benefit of second-line cytotoxic chemotherapy in the second line of treatment for metastatic melanoma. Methods: In a retrospective study, we analyse the outcome of patients with metastatic melanoma who had received two lines or more of cytotoxic treatments in four French dermato-oncology departments between 1999 and 2009. Results:We describe the outcomes for 109 patients. Most of these patients received dacarbazine for the first line of chemotherapy and fotemustine for the second line of chemotherapy (67.0 and 64.2%, respectively). A clinical benefit was observed in 24.1% of the patients and overall survival was 4.1 months after the second-line treatment. At least 23.8% of patients suffered from grade 3 or 4 toxicities. The presence of more than two sites of metastasis and an M1c staging according to the AJCC classification represented negative predictive factors of clinical benefit. Conclusion: This study shows the modest benefit of a second line of cytotoxic chemotherapy in a nonselected population. If eligible, these patients should be proposed for ongoing clinical trials or for targeted therapies.Keywords
This publication has 23 references indexed in Scilit:
- Trends in Dermatology: Melanoma IncidenceArchives of Dermatology, 2010
- Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guidelineEuropean Journal of Cancer, 2010
- Cancer incidence and mortality in France over the period 1980–2005Revue D'Épidémiologie Et de Santé Publique, 2008
- Chemotherapy Compared With Biochemotherapy for the Treatment of Metastatic Melanoma: A Meta-Analysis of 18 Trials Involving 2,621 PatientsJournal of Clinical Oncology, 2007
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study GroupJournal of Clinical Oncology, 2006
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III StudyJournal of Clinical Oncology, 2004
- Global perspectives of contemporary epidemiological trends of cutaneous malignant melanomaBritish Journal of Dermatology, 2004
- Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trialsMelanoma Research, 2001
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999